HRP20160594T1 - Uporaba mimotopa od alfa-sinuklein epitopa za liječenje bolesti s lewyjevim tijelima - Google Patents
Uporaba mimotopa od alfa-sinuklein epitopa za liječenje bolesti s lewyjevim tijelima Download PDFInfo
- Publication number
- HRP20160594T1 HRP20160594T1 HRP20160594TT HRP20160594T HRP20160594T1 HR P20160594 T1 HRP20160594 T1 HR P20160594T1 HR P20160594T T HRP20160594T T HR P20160594TT HR P20160594 T HRP20160594 T HR P20160594T HR P20160594 T1 HRP20160594 T1 HR P20160594T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino acid
- peptide
- composition
- polypeptide
- group
- Prior art date
Links
- 201000002832 Lewy body dementia Diseases 0.000 title claims 3
- 102000003802 alpha-Synuclein Human genes 0.000 title claims 3
- 108090000185 alpha-Synuclein Proteins 0.000 title claims 3
- 208000009829 Lewy Body Disease Diseases 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 11
- 125000000539 amino acid group Chemical group 0.000 claims 9
- 229920001184 polypeptide Polymers 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 235000004279 alanine Nutrition 0.000 claims 6
- 150000001413 amino acids Chemical group 0.000 claims 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 4
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 208000032859 Synucleinopathies Diseases 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 235000009582 asparagine Nutrition 0.000 claims 2
- 229960001230 asparagine Drugs 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 210000004558 lewy body Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 201000007601 neurodegeneration with brain iron accumulation Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Mycology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Claims (15)
1. Sastav, naznačen time, da obuhvaća najmanje jedan peptid ili polipeptid koji sadrži sljedeću aminokiselinsku sekvencu
[image]
gdje
X1 je bilo koji aminokiselinski ostatak,
X2 je aminokiselinski ostatak odabran iz skupine koju čine lizin (K), arginin (R), alanin (A) i histidin (H),
X3 je aminokiselinski ostatak odabran iz skupine koju čine asparagin (N), glutamin (Q), serin (S), glicin (G) i alanin (A), poželjno asparagin (N), serin (S), glicin (G) i alanin (A),
X4 je aminokiselinski ostatak odabran iz skupine koju čine glutaminska kiselina (E), asparaginska kiselina (D) i alanin (A),
X5 je aminokiselinski ostatak odabran iz skupine koju čine glutaminska kiselina (E) i asparaginska kiselina (D),
X6 je aminokiselinski ostatak odabran iz skupine koju čine alanin (A) i tirozin (Y),
X7 je bilo koji aminokiselinski ostatak,
n i m su međusobno neovisno 0 ili neki cijeli broj veći od 0,
i čime aminokiselinska sekvenca prema formuli I nije identična sa sedmomernim fragmentom polipeptida od alfa-sinukleina koji ima aminokiselinsku sekvencu KNEEGAP, ili ga ne sadrži,
gdje navedeni najmanje jedan peptid ili polipeptid ima kapacitet za vezanje na protutijelo specifično za epitop od alfa-sinukleina koji ima aminokiselinsku sekvencu KNEEGAP,
te time, da je za uporabu u prevenciji i/ili liječenju sinukleinopatija.
2. Sastav za uporabu prema zahtjevu 1, naznačen time, da X2 je aminokiselinski ostatak odabran iz skupine koju čine lizin (K) i arginin (R) i/ili X6 je alanin (A).
3. Sastav za uporabu prema zahtjevu 1 ili 2, naznačen time, da peptid ili polipeptid obuhvaća aminokiselinsku sekvencu odabranu iz skupine koju čine (X1)nKNDEGAP(X7)m, (X1)nANEEGAP(X7)m, (X1)nKAEEGAP(X7)m,
(X1)nKNAEGAP(X7)m, (X1)nRNEEGAP(X7)m, (X1)nHNEEGAP(X7)m,
(X1)nKNEDGAP(X7)m, (X1)nKQEEGAP(X7)m, (X1)nKSEEGAP(X7)m,
(X1)nKNDDGAP(X7)m, (X1)nRNDEGAP(X7)m, (X1)nRNEDGAP(X7)m,
(X1)nRQEEGAP(X7)m, (X1)nRSEEGAP(X7)m, (X1)nANDEGAP(X7)m,
(X1)nANEDGAP(X7)m, (X1)nHSEEGAP(X7)m, (X1)nASEEGAP(X7)m,
(X1)nHNEDGAP(X7)m, (X1)nHNDEGAP(X7)m, (X1)nRNAEGAP(X7)m,
(X1)nHNAEGAP(X7)m, (X1)nKSAEGAP(X7)m, (X1)nKSDEGAP(X7)m,
(X1)nKSEDGAP(X7)m, (X1)nRQDEGAP(X7)m, (X1)nRQEDGAP(X7)m,
(X1)nHSAEGAP(X7)m, (X1)nRSAEGAP(X7)m, (X1)nRSDEGAP(X7)m,
(X1)nRSEDGAP(X7)m, (X1)nHSDEGAP(X7)m, (X1)nHSEDGAP(X7)m,
(X1)nRQDDGAP(X7)m, poželjno (X1)nKNDEGAP(X2)m, (X1)nRNEEGAP(X2)m, (X1)nRNDEGAP(X2)m, (X1)nKNAEGAP(X2)m, (X1)nKSDEGAP(X2)m, (X1)nRNAEGAP(X2)m ili (X1)nRSEEGAP(X2)m.
4. Sastav za uporabu prema bilo kojem od zahtjeva 1 do 3, naznačen time, da n i/ili m su 1, a X1 i/ili X7 su cistein (C).
5. Sastav za uporabu prema bilo kojem od zahtjeva 1 do 4, naznačen time, da peptid ili polipeptid sadrži od 7 do 30, poželjno od 7 do 20, još bolje od 7 do 16, te najbolje 8 aminokiselinskih ostataka.
6. Sastav za uporabu prema bilo kojem od zahtjeva 1 do 5, naznačen time, da je sinukleinopatija odabrana iz skupine koju čine poremećaji s Lewyjevim tijelima (LBD), posebno Parkinsonova bolest (PD), Parkinsonova bolest s demencijom (PDD) i demencija s Lewyjevim tijelima (DLB), kao i višestruka sistemska atrofija (MSA) ili neurodegeneracija s akumuliranjem željeza u mozgu, tipa I (NBIA tip I).
7. Sastav za uporabu prema bilo kojem od zahtjeva 1 do 6, naznačen time, da je najmanje jedan peptid ili polipeptid spojen na farmaceutski prihvatljiv nosač, poželjno na KLH (Keyhole Limpet Hemocyanin).
8. Sastav za uporabu prema bilo kojem od zahtjeva 1 do 7, naznačen time, da je najmanje jedan peptid ili polipeptid formuliran za intravenoznu, subkutanu, intradermalnu ili intramuskularnu primjenu.
9. Sastav za uporabu prema bilo kojem od zahtjeva 1 do 8, naznačen time, da je najmanje jedan peptid ili polipeptid formuliran s jednim pomoćnim sredstvom, poželjno s aluminijevim hidroksidom.
10. Sastav za uporabu prema bilo kojem od zahtjeva 1 do 9, naznačen time, da se najmanje jedan peptid ili polipeptid nalazi u sastavu u količini od 0,1 ng do 10 mg, poželjno od 10 ng do 1 mg, posebno od 100 ng do 100 μg.
11. Peptid, naznačen time, da ima aminokiselinsku sekvencu odabranu iz skupine koju čine (X1)nKNDEGAP(X7)m, (X1)nANEEGAP(X7)m, (X1)nKAEEGAP(X7)m, (X1)nKNAEGAP(X7)m, (X1)nRNEEGAP(X7)m, (X1)nHNEEGAP(X7)m, (X1)nKNEDGAP(X7)m, (X1)nKQEEGAP(X7)m, (X1)nKSEEGAP(X7)m, (X1)nKNDDGAP(X7)m, (X1)nRNDEGAP(X7)m, (X1)nRNEDGAP(X7)m, (X1)nRQEEGAP(X7)m, (X1)nRSEEGAP(X7)m, (X1)nANDEGAP(X7)m, (X1)nANEDGAP(X7)m, (X1)nHSEEGAP(X7)m, (X1)nASEEGAP(X7)m, (X1)nHNEDGAP(X7)m, (X1)nHNDEGAP(X7)m, (X1)nRNAEGAP(X7)m, (X1)nHNAEGAP(X7)m, (X1)nKSAEGAP(X7)m, (X1)nKSDEGAP(X7)m, (X1)nKSEDGAP(X7)m, (X1)nRQDEGAP(X7)m,
(X1)nRQEDGAP(X7)m, (X1)nHSAEGAP(X7)m, (X1)nRSAEGAP(X7)m,
(X1)nRSDEGAP(X7)m, (X1)nRSEDGAP(X7)m, (X1)nHSDEGAP(X7)m,
(X1)nHSEDGAP(X7)m i (X1)nRQDDGAP(X7)m, pri čemu su X1 i X7 cistein,
dok su n i m neovisno 0 ili 1.
12. Peptid prema zahtjevu 11, naznačen time, da je peptid spojen na farmaceutski prihvatljiv nosač, poželjno na KLH (Keyhole Limpet Hemocyanin).
13. Peptid prema zahtjevu 11 ili 12, naznačen time, da se upotrebljava u prevenciji i/ili liječenju sinukleinopatija.
14. Farmaceutska formulacija, naznačena time, da obuhvaća najmanje jedan peptid prema zahtjevu 11 ili 12.
15. Farmaceutska formulacija prema zahtjevu 14, naznačena time, da se upotrebljava kao cjepivo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0132409A AT508638B1 (de) | 2009-08-21 | 2009-08-21 | Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien |
| PCT/AT2010/000303 WO2011020133A1 (en) | 2009-08-21 | 2010-08-20 | Use of mimotopes of alpha-synuclein epitopes for treating lewy body diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160594T1 true HRP20160594T1 (hr) | 2016-07-29 |
Family
ID=42940852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160594TT HRP20160594T1 (hr) | 2009-08-21 | 2016-06-01 | Uporaba mimotopa od alfa-sinuklein epitopa za liječenje bolesti s lewyjevim tijelima |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8828942B2 (hr) |
| EP (1) | EP2467153B1 (hr) |
| JP (2) | JP2013502379A (hr) |
| KR (2) | KR20140141651A (hr) |
| CN (1) | CN102596224B (hr) |
| AT (1) | AT508638B1 (hr) |
| AU (1) | AU2010283948B2 (hr) |
| BR (1) | BR112012003800A2 (hr) |
| CA (1) | CA2771429A1 (hr) |
| CY (1) | CY1117582T1 (hr) |
| DK (1) | DK2467153T3 (hr) |
| ES (1) | ES2573662T3 (hr) |
| HK (1) | HK1170658A1 (hr) |
| HR (1) | HRP20160594T1 (hr) |
| HU (1) | HUE027563T2 (hr) |
| IL (1) | IL218207A0 (hr) |
| MX (1) | MX2012002153A (hr) |
| PL (1) | PL2467153T3 (hr) |
| PT (1) | PT2467153E (hr) |
| RU (1) | RU2532351C2 (hr) |
| SI (1) | SI2467153T1 (hr) |
| WO (1) | WO2011020133A1 (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2579042T3 (pl) | 2011-10-04 | 2014-12-31 | Affiris Ag | Sposób wykrywania przeciwciał swoistych wobec Aß w próbce biologicznej |
| EP2659907A1 (en) | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
| EP2659906A1 (en) * | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
| WO2015075011A1 (en) | 2013-11-21 | 2015-05-28 | F. Hoffmann-La Roche Ag | ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE |
| CA3003943A1 (en) | 2015-11-03 | 2017-05-11 | Affiris Ag | Method for vaccination against a self-antigen in a human patient |
| KR101726549B1 (ko) | 2016-06-29 | 2017-04-12 | 정상문 | 모바일 실시간 시뮬레이션 게임에서의 터치 조작 방식 |
| KR102087494B1 (ko) | 2018-03-15 | 2020-03-10 | 정상문 | 모바일 실시간 시뮬레이션 게임에서 객체를 표시하는 방법 |
| AU2019406749A1 (en) | 2018-12-20 | 2021-05-27 | Saiba AG | Virus-like particles of CMV modified by fusion |
| US20230242601A1 (en) | 2020-07-29 | 2023-08-03 | Tohoku University | Peptide used to prevent or treat synucleinopathy |
| JP2023536497A (ja) | 2020-08-04 | 2023-08-25 | エイシー イミューン ソシエテ アノニム | 免疫原性化合物 |
| US20240189407A1 (en) | 2021-04-12 | 2024-06-13 | Saiba AG | Modified virus-like particles of bacteriophage ap205 |
| WO2022265091A1 (ja) * | 2021-06-18 | 2022-12-22 | 住友ファーマ株式会社 | ヒトαシヌクレインのエピトープペプチド及び該ペプチドを含む医薬組成物 |
| AU2023219059A1 (en) | 2022-02-09 | 2024-07-25 | Ac Immune Sa | Anti-alpha-synuclein therapeutic vaccines |
| AU2023223603A1 (en) | 2022-02-28 | 2024-08-22 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN. |
| AU2023225283A1 (en) | 2022-02-28 | 2024-08-22 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN. |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007325595A (ja) * | 2000-12-22 | 2007-12-20 | Locomogene Inc | 滑膜細胞タンパク質 |
| AU2002357007A1 (en) * | 2001-11-21 | 2003-06-10 | New York University | SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID Beta, PRION PROTEIN, AMYLIN, Alpha-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO |
| US8697082B2 (en) * | 2002-11-01 | 2014-04-15 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US8506959B2 (en) * | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| TW200509968A (en) * | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US20080014194A1 (en) * | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| US7358331B2 (en) * | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| PT1633189T (pt) | 2003-05-19 | 2017-10-04 | Prothena Biosciences Ltd | Fragmentos truncados de alfa-sinucleína em doença com corpos de lewy |
| JPWO2004113535A1 (ja) | 2003-06-22 | 2007-09-20 | 早出 広司 | 凝集抑制作用を有するシヌクレイン変異体 |
| WO2006004066A1 (ja) * | 2004-07-02 | 2006-01-12 | Locomogene, Inc. | S1-5を含有するタンパク質製剤 |
| MX2007001679A (es) * | 2004-08-09 | 2007-05-23 | Elan Pharm Inc | Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica. |
| ZA200701531B (en) * | 2004-08-09 | 2009-03-25 | Elan Pharm Inc | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| KR101236611B1 (ko) * | 2005-12-12 | 2013-03-04 | 에이씨 이뮨 에스.에이. | 치료 백신 |
| PT2370466E (pt) * | 2008-12-19 | 2015-09-21 | Univ Zuerich | Autoanticorpos humanos anti-alfa-sinucleína |
-
2009
- 2009-08-21 AT AT0132409A patent/AT508638B1/de not_active IP Right Cessation
-
2010
- 2010-08-20 BR BR112012003800A patent/BR112012003800A2/pt not_active IP Right Cessation
- 2010-08-20 HU HUE10747562A patent/HUE027563T2/en unknown
- 2010-08-20 DK DK10747562.6T patent/DK2467153T3/en active
- 2010-08-20 JP JP2012524998A patent/JP2013502379A/ja active Pending
- 2010-08-20 US US13/391,552 patent/US8828942B2/en not_active Expired - Fee Related
- 2010-08-20 CA CA2771429A patent/CA2771429A1/en not_active Abandoned
- 2010-08-20 PT PT107475626T patent/PT2467153E/pt unknown
- 2010-08-20 MX MX2012002153A patent/MX2012002153A/es active IP Right Grant
- 2010-08-20 EP EP10747562.6A patent/EP2467153B1/en active Active
- 2010-08-20 KR KR1020147028566A patent/KR20140141651A/ko not_active Application Discontinuation
- 2010-08-20 RU RU2012110582/15A patent/RU2532351C2/ru not_active IP Right Cessation
- 2010-08-20 CN CN201080047744.9A patent/CN102596224B/zh not_active Expired - Fee Related
- 2010-08-20 KR KR1020127007123A patent/KR101517447B1/ko not_active IP Right Cessation
- 2010-08-20 WO PCT/AT2010/000303 patent/WO2011020133A1/en active Application Filing
- 2010-08-20 ES ES10747562.6T patent/ES2573662T3/es active Active
- 2010-08-20 SI SI201031190A patent/SI2467153T1/sl unknown
- 2010-08-20 AU AU2010283948A patent/AU2010283948B2/en not_active Ceased
- 2010-08-20 PL PL10747562.6T patent/PL2467153T3/pl unknown
-
2012
- 2012-02-20 IL IL218207A patent/IL218207A0/en unknown
- 2012-11-05 HK HK12111092.0A patent/HK1170658A1/zh not_active IP Right Cessation
-
2014
- 2014-09-03 JP JP2014179547A patent/JP5901714B2/ja not_active Expired - Fee Related
-
2016
- 2016-06-01 HR HRP20160594TT patent/HRP20160594T1/hr unknown
- 2016-06-01 CY CY20161100480T patent/CY1117582T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2532351C2 (ru) | 2014-11-10 |
| AU2010283948A1 (en) | 2012-03-29 |
| KR20140141651A (ko) | 2014-12-10 |
| DK2467153T3 (en) | 2016-06-06 |
| SI2467153T1 (sl) | 2016-07-29 |
| US20120156234A1 (en) | 2012-06-21 |
| AT508638B1 (de) | 2011-08-15 |
| HK1170658A1 (zh) | 2013-03-08 |
| EP2467153B1 (en) | 2016-03-02 |
| KR20120059562A (ko) | 2012-06-08 |
| PT2467153E (pt) | 2016-06-08 |
| MX2012002153A (es) | 2012-03-14 |
| EP2467153A1 (en) | 2012-06-27 |
| IL218207A0 (en) | 2012-04-30 |
| US8828942B2 (en) | 2014-09-09 |
| JP5901714B2 (ja) | 2016-04-13 |
| BR112012003800A2 (pt) | 2016-11-22 |
| AU2010283948B2 (en) | 2015-01-22 |
| CN102596224A (zh) | 2012-07-18 |
| ES2573662T3 (es) | 2016-06-09 |
| WO2011020133A1 (en) | 2011-02-24 |
| KR101517447B1 (ko) | 2015-05-28 |
| AT508638A1 (de) | 2011-03-15 |
| RU2012110582A (ru) | 2013-09-27 |
| CY1117582T1 (el) | 2017-04-26 |
| HUE027563T2 (en) | 2016-10-28 |
| CN102596224B (zh) | 2015-12-09 |
| JP2013502379A (ja) | 2013-01-24 |
| JP2015038078A (ja) | 2015-02-26 |
| CA2771429A1 (en) | 2011-02-24 |
| PL2467153T3 (pl) | 2016-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160594T1 (hr) | Uporaba mimotopa od alfa-sinuklein epitopa za liječenje bolesti s lewyjevim tijelima | |
| HRP20140586T1 (hr) | Peptidi za lijeäśenje beta-amiloidoze | |
| HRP20151148T1 (hr) | Mimotopi od alfa-sinukleina i njihova cjepiva za lijeäśenje neurodegenerativnih poremeä†aja | |
| RU2013154066A (ru) | Новые производные оксинтомодулина и содержащая их фармацевтическая композиция для лечения ожирения | |
| PH12019500074A1 (en) | Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease | |
| NZ628987A (en) | Extended recombinant polypeptides and compositions comprising same | |
| RU2021105821A (ru) | Соединения, связывающие рецептор il-2 | |
| RU2012101274A (ru) | Соединения глюкагона, активные в отношении рецептора gip | |
| JP2013543497A5 (hr) | ||
| RU2014114506A (ru) | Вакцина | |
| RU2012139432A (ru) | Полипептиды | |
| RU2010101232A (ru) | Производное инсулинотропного пептида, содержащее модифицированную n-концевую аминокислоту | |
| JP2011522842A5 (hr) | ||
| WO2015157508A1 (en) | Peptidomimetic macrocycles with pth activity | |
| CA2092075A1 (en) | Peptide-based inhibitors of hiv replication | |
| RU2009105176A (ru) | Дипептидные миметики нейротрофинов ngf и bdnf | |
| JP2006506942A5 (hr) | ||
| MX2009010965A (es) | Péptidos de tem8 y vacunas que los contienen. | |
| AR092316A1 (es) | Composiciones | |
| MX2016011852A (es) | Composiciones y metodos para prevenir o tratar la disfuncion cronica del aloinjerto pulmonar (clad) y fibrosis pulmonar idiopatica (fpi). | |
| JPH07324097A (ja) | インターロイキン６拮抗剤、及びペプチド類または医薬として許容されるその塩類 | |
| NZ736652A (en) | Short synthetic peptide for treating diseases and/or conditions related to angiogenesis | |
| RU2014103246A (ru) | Соединения и фармацевтические комбинации для лечения нейродегенеративных и ишемических болезней мозга | |
| HRP20240906T1 (hr) | Agonisti crf2 receptora i njihova primjena u terapiji | |
| RU2012108179A (ru) | Новый пептид и его применение |